News & Publications Press Releases Featured Press Releases April 19, 2026 EpiBiologics Doses First Patient with EPI-326 Bispecific Antibody in Global Phase 1 Study for EGFR-Driven Solid Tumors Press Releases April 19, 2026 Press Releases April 19, 2026 Press Releases January 8, 2026 EpiBiologics Closes $107M Series B to Advance Pipeline of Novel Bispecific Antibodies to Selectively Degrade Extracellular Protein Targets in Oncology and Immunology Press Releases January 8, 2026 Press Releases January 8, 2026 Press Releases April 28, 2025 EpiBiologics Presents First Data on c-Met Degrading Bispecific Antibody Press Releases April 28, 2025 Press Releases April 28, 2025 Press Releases November 4, 2024 EpiBiologics to Present Data Demonstrating Disease-Selective Extracellular Protein Degradation and Platform Breadth at Upcoming Scientific Meetings Press Releases November 4, 2024 Press Releases November 4, 2024 Press Releases April 8, 2024 EpiBiologics Extracellular Protein Degraders Demonstrate Robust Preclinical Anti-tumor Activity and Survival Benefit Press Releases April 8, 2024 Press Releases April 8, 2024 Press Releases July 20, 2023 EpiBiologics Appoints Ann Lee-Karlon as Chief Executive Officer and President, Extends Series A Financing to Over $70 Million Press Releases July 20, 2023 Press Releases July 20, 2023 Press Releases March 22, 2023 EpiBiologics Launches with $50 million Series A Financing to Advance Next-Generation Protein Degradation Platform Press Releases March 22, 2023 Press Releases March 22, 2023 Publications & Presentations Featured Publications April 28, 2025 Discovery of cMET degrading bispecific antibodies (EpiTACs) for NSCLC and other cMET driven tumors Publications April 28, 2025 Publications April 28, 2025 Publications September 22, 2022 Modular cytokine receptor-targeting chimeras for targeted degradation of cell surface and extracellular proteins Publications September 22, 2022 Publications September 22, 2022 Publications April 28, 2022 Roadmap for Optimizing and Broadening Antibody-Based PROTACs for Degradation of Cell Surface Proteins Publications April 28, 2022 Publications April 28, 2022 Publications January 4, 2021 Development of Antibody-Based PROTACs for the Degradation of the Cell-Surface Immune Checkpoint Protein PD-L1 Publications January 4, 2021 Publications January 4, 2021 In the News Featured In the News April 21, 2026 Biologic degraders push forward in the clinic In the News April 21, 2026 In the News April 21, 2026 In the News January 8, 2026 Google, Johnson & Johnson back protein degrader start-up In the News January 8, 2026 In the News January 8, 2026 In the News January 8, 2026 Former Genentech leaders’ protein degrader startup nets $107M In the News January 8, 2026 In the News January 8, 2026 In the News April 8, 2024 AACR 2024: EpiBiologics Advances Degraders of Membrane-Bound Proteins In the News April 8, 2024 In the News April 8, 2024 In the News March 22, 2023 At EpiBiologics, a pair of Genentech alumni wants to make next-gen protein degraders In the News March 22, 2023 In the News March 22, 2023
